However, despite our criticism, it is only fair to state here that according to our judgement the very elaborate study by Liuet al.1 believably shows (1) howNKILA can bind (in vitro) to NF-κB, (2) thatNKILA can interfere with functions that involve NF-κB pathways, and (3) that lowNKILA expression predicts poor clinical outcome in patients with breast cancer. Here, NFKB1 is linked to breast carcinoma.